Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Background: Multiple myeloma (MM) is a malignant plasma cell disease. In recent years, several systematic reviews, and meta-analyses have been published on treatment protocols, including autologous stem cell transplantation for MM.

Methods: Web of Science, PubMed, Embase, and Cochrane Library were searched to systematically summarize the quality of the methodology and evidence of meta-analyses regarding treatment of MM including autologous stem cell transplantation.

Results: Total 11 meta-analyses were included. The preferred reporting items for systematic reviews and meta-analyses evaluation revealed that the quality of included reviews was affected by possible unevaluated bias between studies and the lack of protocol and registration. The AMSTAR2 scale indicated that the quality of the methodology of included reviews ranged from very low to moderate. The grading, assessment, development, and evaluation of recommendations evaluation showed that among the included outcome indicators, most of them are of low quality.

Conclusion: This overview suggested that the combination of drugs has improved patient survival rates, efficacy and safety compared with the standard regimen. However, the strength of the evidence is uneven and due to methodological errors, the results should be interpreted with caution in order to provide a reference for further improvement of the study design. The methodological quality of the relevant meta-analysis needs to be further improved.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553094PMC
http://dx.doi.org/10.1097/MD.0000000000035456DOI Listing

Publication Analysis

Top Keywords

autologous stem
12
stem cell
12
systematic reviews
12
multiple myeloma
8
reviews meta-analyses
8
including autologous
8
quality methodology
8
included reviews
8
reviews
5
treatment multiple
4

Similar Publications

Background: Bone marrow (BM) Measurable Residual Disease (MRD) assessments underestimate disease burden in multiple myeloma, as focal lesions can exist outside the marrow. Functional imaging, like positron emission tomography-computed tomography (PET-CT), offers valuable insights into residual disease beyond the marrow. Combining marrow flow cytometry (FCM) with PET-CT for a composite MRD (cMRD) assessment before and after autologous stem cell transplant (ASCT) is expected to provide prognostic information, particularly in settings where patients receive extended duration of anti-myeloma therapy prior to ASCT.

View Article and Find Full Text PDF

Facial nerve pathology: emerging strategies for regeneration and functional restoration.

J Mater Chem B

September 2025

Nebraska Translational Research Center (NTRC), Department of Growth and Development, College of Dentistry, University of Nebraska Medical Center, Joseph D. & Millie E. Williams Science Hall, 525 S 42nd St, Room No 3.0.010, Omaha, NE 68105-6040, USA.

Facial nerve injuries cause significant functional impairments, affect facial expressions, speech, and overall quality of life. This article explores advances in facial nerve regeneration, encompassing both conventional and emerging therapeutic strategies. The regenerative process involves Wallerian degeneration, axonal regrowth, and target muscle reinnervation, where the distal axon degrades and the proximal axon initiates sprouting to restore connectivity.

View Article and Find Full Text PDF

Functional high risk multiple myeloma (FHRMM) remains a challenging entity with poor outcomes and limited survival, and there is no international consensus on optimal second-line therapeutic strategies in relapsed/refractory patients. In this multicenter real-world retrospective study, we investigated clinical characteristics and outcomes of a total of 62 FHRMM patients previously treated with a first-line daratumumab-based quadruplet regimen or who relapsed within 12 months after frontline autologous stem cell transplantation (ASCT). In our cohort, the overall response rate was 61%, with 42% of patients achieving a very good partial response (VGPR) or better.

View Article and Find Full Text PDF

Pediatric pancreatic neuroblastoma is a rare cancer in children, with only limited cases available in the literature. We report a case of a 4-year-old girl diagnosed with high-risk pancreatic neuroblastoma. The girl was treated with induction chemotherapy followed by autologous stem cell transplant and maintenance with 13-cis-retinoic acid.

View Article and Find Full Text PDF